Clinical Trial Update: Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/2 study evaluating Tarlatamab and Sacituzumab Govitecan in previously treated extensive-stage small cell lung can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer
• Extrapulmonary Neuroendocrine Carcinoma

Drugs mentioned

• Sacituzumab Govitecan (sacituzumab govitecan)
• Tarlatamab

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING